The clinical trial, conducted in partnership with AstraZeneca, aimed to reduce cardiovascular death and recurrent events in patients suffering from transthyretin-mediated amyloid cardiomyopathy. Following the disclosure that the study failed to achieve these results, the stock price shed nearly $17 per share during pre-market trading.
Ionis Pharmaceuticals faces shareholder probe after trial failure
Ionis Pharmaceuticals shares plummeted more than 20% on July 9, 2026, after the company announced its Phase-3 CARDIO-TTRansform trial failed to meet its primary endpoint. The sudden market contraction has triggered a formal investigation by SueWallSt into whether the firm misled investors regarding the program's potential.
Legal representatives from Levi & Korsinsky LLP are now scrutinizing whether Ionis Pharmaceuticals provided accurate disclosures to shareholders prior to the negative readout. Investors who purchased IONS stock and sustained financial losses are being invited to submit documentation for a potential securities claim. The firm notes that participation does not require court appearances or upfront legal fees, as cases of this nature are typically handled on a contingency basis.
Comments (0)
No comments yet. Be the first!